Cancer cells with homologous recombination (HR) deficiency are known to be exquisitely sensitive to poly[adenosine 5′-diphosphate (ADP)-ribose] polymerase 1 (PARP1) inhibitors (PARPi) (1). Here, PARP1 is linked to cancer.